Neovascular Age-Related Macular Degeneration

In this video, Donald J. D’Amico, MD, discusses data from the phase 2 LUNA trial of Ixo-vec intravitreal gene therapy for neovascular age-related macular degeneration.

Healio’s top video perspectives from the American Society of Retina Specialists meeting highlight faricimab in diabetic macular edema as well as an axitinib implant for wet age-related macular degeneration.

Sozinibercept, a VEGF-C and -D “trap” inhibitor, showed improved durability in patients with retinal diseases when delivered as a combination therapy vs. anti-VEGF-A monotherapies, according to a study.

The first analysis of real-world outcomes in patients with neovascular age-related macular degeneration treated with pegcetacoplan for geographic atrophy demonstrated similar safety seen in clinical trials, according to a study.

Need to catch up on anything from this year’s Clinical Trials at the Summit? Here are some of Healio’s latest videos from the meeting.

A review of currently available data suggests that there is little or no difference in efficacy and safety between anti-VEGF biosimilars approved for neovascular age-related macular degeneration and their reference products.

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Carlos Quezada-Ruiz, MD, FASRS, of Genentech/Roche shares an update on Susvimo and the port delivery platform.

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Adam Turpcu, PhD, of Adverum Biotechnologies discusses Ixo-vec for neovascular age-related macular degeneration.

The FDA approved FYB203/Ahzantive as a biosimilar to Eylea, according to a joint press release from Formycon and Klinge Biopharma.